Redeye comments on SynAct Pharma's Q1 report. The main event since our Q4 update was the directed share issue of SEK52m, which strengthens the balance sheet over the ADVANCE phase IIb readout in June. The RESOVIR-2 study opened recruitment in late March.
LÄS MER
